Novoheart Competitors

ProMetic Life Sciences (TSE:PLI) and Novoheart (CVE:NVH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Analyst Ratings

This is a summary of current recommendations for ProMetic Life Sciences and Novoheart, as provided by MarketBeat.

Valuation and Earnings

This table compares ProMetic Life Sciences and Novoheart's revenue, earnings per share and valuation.

Novoheart has lower revenue, but higher earnings than ProMetic Life Sciences. Novoheart is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ProMetic Life Sciences and Novoheart's net margins, return on equity and return on assets.

Novoheart (CVE:NVH) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Valuation & Earnings

This table compares Novoheart and Medicenna Therapeutics' revenue, earnings per share and valuation.

Medicenna Therapeutics has lower revenue, but higher earnings than Novoheart. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Novoheart, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novoheart and Medicenna Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for Novoheart and Medicenna Therapeutics, as reported by MarketBeat.

Summary

Novoheart beats Medicenna Therapeutics on 3 of the 3 factors compared between the two stocks.

Novoheart (CVE:NVH) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares Novoheart and Emblem's top-line revenue, earnings per share and valuation.

Novoheart has higher earnings, but lower revenue than Emblem. Novoheart is trading at a lower price-to-earnings ratio than Emblem, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Novoheart and Emblem, as provided by MarketBeat.com.

Profitability

This table compares Novoheart and Emblem's net margins, return on equity and return on assets.

Summary

Novoheart beats Emblem on 3 of the 5 factors compared between the two stocks.

Neptune Wellness Solutions (TSE:NEPT) and Novoheart (CVE:NVH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Profitability

This table compares Neptune Wellness Solutions and Novoheart's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for Neptune Wellness Solutions and Novoheart, as reported by MarketBeat.com.

Neptune Wellness Solutions currently has a consensus target price of C$4.63, suggesting a potential upside of 214.63%. Given Neptune Wellness Solutions' higher possible upside, equities analysts clearly believe Neptune Wellness Solutions is more favorable than Novoheart.

Valuation & Earnings

This table compares Neptune Wellness Solutions and Novoheart's revenue, earnings per share (EPS) and valuation.

Novoheart has lower revenue, but higher earnings than Neptune Wellness Solutions. Novoheart is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

Neptune Wellness Solutions beats Novoheart on 4 of the 7 factors compared between the two stocks.

Novoheart (CVE:NVH) and IMV (TSE:IMV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Earnings and Valuation

This table compares Novoheart and IMV's revenue, earnings per share and valuation.

Novoheart has higher revenue and earnings than IMV. Novoheart is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novoheart and IMV's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and price targets for Novoheart and IMV, as provided by MarketBeat.

IMV has a consensus price target of C$5.08, indicating a potential upside of 49.95%. Given IMV's higher possible upside, analysts plainly believe IMV is more favorable than Novoheart.

Novoheart (CVE:NVH) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Valuation and Earnings

This table compares Novoheart and Resverlogix's top-line revenue, earnings per share (EPS) and valuation.

Resverlogix has lower revenue, but higher earnings than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novoheart and Resverlogix's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for Novoheart and Resverlogix, as provided by MarketBeat.com.

Summary

Resverlogix beats Novoheart on 2 of the 3 factors compared between the two stocks.